20294-50-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
4-bromo-2-methyl-6-nitrophenol is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the creation of a wide range of compounds with potential therapeutic and agricultural applications.
Used in Enzyme Detection and Quantification:
In the field of biology, 4-bromo-2-methyl-6-nitrophenol is used as a substrate for the detection and quantification of nitroreductase enzymes. These enzymes are involved in the reduction of nitro groups, and the compound's reactivity with these enzymes helps in studying their activity and function in biological systems.
Used in Organic Synthesis:
4-bromo-2-methyl-6-nitrophenol is utilized as a reagent in organic synthesis, where its functional groups can be manipulated to form a variety of organic compounds. Its presence in reactions can lead to the formation of new chemical entities with potential applications in various industries.
Used in Laboratory Research:
Due to its unique properties and reactivity, 4-bromo-2-methyl-6-nitrophenol is used in laboratory research to explore its potential applications and to understand its chemical behavior. Researchers use 4-bromo-2-methyl-6-nitrophenol to investigate new synthetic pathways and to develop novel compounds with specific properties.

InChI:InChI=1/C7H6BrNO3/c1-4-2-5(8)3-6(7(4)10)9(11)12/h2-3,10H,1H3

Upstream product

• 109-95-5 ethyl nitrite 
• 64-17-5 ethanol 
• 36194-82-8 5-bromo-2-hydroxy-3-methylbenzenecarboxylic acid 
• 609-22-3 2,4-dibromo-6-methylphenol 
• 2362-12-1 4-Bromo-2-methylphenol 
• 583-75-5 4-Bromo-2-methylaniline 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 95-48-7 ortho-cresol 

Downstream Products

• 888731-60-0 2-chloro-N-(2-hydroxy-3-methylphenyl)-acetamide 
• 102065-94-1 8-methyl-4H-benz[1,4]oxazin-3-one 
• 850896-45-6 8-methyl-3,4-dihydro-2H-benz[1,4]oxazine 
• 1221500-65-7 6-[5-(4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]-8-methyl-2H-1,4-benzoxazin-3(4H)-one 
• 943994-87-4 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-1,4-benzoxazin-3(4H)-one 
• 121564-97-4 6-bromo-8-methyl-2H-1,4-benzoxazin-3(4H)-one 
• 942215-50-1 2-(4-aminophenyl)-7-methyl-1,3-benzoxazole-5-carbonitrile 
• 942215-52-3 4-(5-bromo-7-methyl-1,3-benzoxazol-2-yl)aniline 
• 942215-51-2 5-bromo-7-methyl-2-(4-nitrophenyl)-1,3-benzoxazole 
• 1268599-73-0 C₂₈H₂₅N₅O₄ 
• 1268599-72-9 C₃₀H₂₉N₅O₄ 
• 1268599-71-8 C₂₈H₂₅N₅O₄ 
• 1268599-70-7 C₂₉H₂₇N₅O₄ 
• 942214-09-7 C₂₇H₂₄ClN₅O₂ 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND METHODS OF USE

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Electrochemical Nitration with Nitrite

Aromatic nitration has tremendous importance in organic chemistry as nitroaromatic compounds serve as versatile building blocks. This study represents the electrochemical aromatic nitration with NBu4NO2, which serves a dual role as supporting electrolyte and as a safe, readily available, and easy-to-handle nitro source. Stoichiometric amounts of 1,1,1-3,3,3-hexafluoroisopropan-2-ol (HFIP) in MeCN significantly increase the yield by solvent control. The reaction mechanism is based on electrochemical oxidation of nitrite to NO2, which initiates the nitration reaction in a divided electrolysis cell with inexpensive graphite electrodes. Overall, the reaction is demonstrated for 20 examples with yields of up to 88 %. Scalability is demonstrated by a 13-fold scale-up.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

SUBSTITUTED NITROGEN CONTAINING COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Novel benzoxazolone compound

PROBLEM TO BE SOLVED: To provide a therapeutic agent for diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small diameter fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria or multiple sclerosis. SOLUTION: There is provided a benzoxazolone compound represented by the formula (1) or a pharmaceutically acceptable salt. (1), where R1 and R2 are each independently H or C1-6 alkyl, where the alkyl may be substituted by hydroxy, C1-4 alkylsulfonyl, aminocarbonyl or 4 to 7-membered heterocycloalkyl, or the like, L is C1-6 alkylene, R3 is C1-6 alkyl, C3-7 cycloalkyl, where the cycloalkyl may be substituted by halogen or hydroxy or the like, C6-10 aryl, where the aryl may be substituted by halogen, C1-4 alkyl or C1-4 haloalkyl or the like, R4 is H, halogen or C1-4 alkyl. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in cynoCETP transgenic mice

We describe structure-activity studies leading to the discovery of 2-arylbenzoxazole 3, the first in a series to raise serum high-density lipoprotein cholesterol levels in transgenic mice. Replacement of the 4-piperidinyloxy moiety with piperazinyl provid

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I